Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

Patients also have to deal with changes to their health insurance at the start of a new year, and more employers have ...

In a separate development, Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive ...

Disc Medicine (IRON) stock and Sanofi (SNY) stock are in focus as the FDA delays reviews of their drugs selected for National Priority Review vouchers. Read more here.

The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...

According to firm-reported figures, Morgan & Morgan had 295 cases go to trial which ultimately resolved favorably for the plaintiff. The firm secured $1,098,230,342 in jury verdicts for its clients, ...

The new drugs could become the way forward for medicated weight loss as clinical trials reveal optimistic results ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.